Solosec Archives - Medical Design Sourcing

Image courtesy of Pixabay

The pandemic continued to remake the pharma and biotech industry this past year. A handful of companies fared exceptionally well at commercializing COVID-19 therapies. This fact promises to lead to sizable shifts in the rankings of pharma leaders. These trends were not yet evident in our spring roundup of the 50 largest pharma companies, which drew revenue figures from the prior year. But in 2021, companies like Pfizer and Moderna sold tens of billions of dollars of COVID-19 vaccine alone. As a result of the ongoing pandemic, significant shifts are likely in 2022’s forthcoming ranking of pharma leaders.

Here, we provide an opportunity to review the 2021 pharma landscape, including stories that received the most attention on social media.

1. Pharma 50: The 50 largest pharmaceutical companies in the world

The top 50 largest pharmaceutical companies raked in $851 billion…

Mumbai, India–headquartered Lupin Pharmaceuticals (NYSE:LUPIN) has received an expanded indication for Solosec (secnidazole) to cover the treatment of trichomoniasis in adult patients and their partners.

The drug scored an initial FDA approval in 2017 for bacterial vaginosis (BV) in adult women.

Solosec is now the only single-dose oral drug that has an FDA indication for both trichomoniasis and BV.

The most recent approval follows a Phase 3 clinical trial that showed a 92.2% cure rate for patients with trichomoniasis, a common sexually transmitted disease (STD) resulting from infection with a protozoan parasite. CDC estimated there were two million trichomoniasis infections in the U.S. in 2018. Only about 30% of those with the condition, however, develop symptoms.

In the Phase 3 trial mentioned above, clinical trial investigators reported no serious adverse events. Some 2.7% of drug recipients in the trial had vulvovaginal candidiasis and 2.7…

Solosec

The top 5 drug discovery stories of 2021

Lupin wins FDA approval for Solosec as treatment of trichomoniasis